GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » C4X Discovery Holdings PLC (FRA:C4J) » Definitions » Debt-to-EBITDA

C4X Discovery Holdings (FRA:C4J) Debt-to-EBITDA : 0.01 (As of Jan. 2024)


View and export this data going back to 2020. Start your Free Trial

What is C4X Discovery Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

C4X Discovery Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was €0.30 Mil. C4X Discovery Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was €0.01 Mil. C4X Discovery Holdings's annualized EBITDA for the quarter that ended in Jan. 2024 was €41.96 Mil. C4X Discovery Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 was 0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for C4X Discovery Holdings's Debt-to-EBITDA or its related term are showing as below:

FRA:C4J' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.88   Med: -0.07   Max: 0.03
Current: 0.03

During the past 12 years, the highest Debt-to-EBITDA Ratio of C4X Discovery Holdings was 0.03. The lowest was -1.88. And the median was -0.07.

FRA:C4J's Debt-to-EBITDA is ranked better than
93.48% of 276 companies
in the Biotechnology industry
Industry Median: 1.34 vs FRA:C4J: 0.03

C4X Discovery Holdings Debt-to-EBITDA Historical Data

The historical data trend for C4X Discovery Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

C4X Discovery Holdings Debt-to-EBITDA Chart

C4X Discovery Holdings Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.05 -0.07 -0.07 -0.03

C4X Discovery Holdings Semi-Annual Data
Jul14 Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jul19 Jan20 Jul20 Jan21 Jul21 Jan22 Jul22 Jan23 Jul23 Jan24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.08 -0.06 -0.03 0.01

Competitive Comparison of C4X Discovery Holdings's Debt-to-EBITDA

For the Biotechnology subindustry, C4X Discovery Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


C4X Discovery Holdings's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, C4X Discovery Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where C4X Discovery Holdings's Debt-to-EBITDA falls into.



C4X Discovery Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

C4X Discovery Holdings's Debt-to-EBITDA for the fiscal year that ended in Jul. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.393 + 0.101) / -15.207
=-0.03

C4X Discovery Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.295 + 0.006) / 41.962
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jan. 2024) EBITDA data.


C4X Discovery Holdings  (FRA:C4J) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


C4X Discovery Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of C4X Discovery Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


C4X Discovery Holdings (FRA:C4J) Business Description

Traded in Other Exchanges
Address
53 Portland Street, Manchester One, Manchester, GBR, M1 3LD
C4X Discovery Holdings PLC is a drug discovery and development company. It has various proprietary and synergistic software platforms Taxonomy3, Conformetrix, and 4Sight. Taxonomy3 is a novel in silico platform technology that utilizes proprietary ground-breaking mathematical algorithms to perform complex multivariate analysis of genetic data. Conformetrix enables rational, accelerated 4D structural drug design using experimental data rather than theoretical data. The 4Sight allows its research scientists to view, understand and interrogate the complex, multidimensional molecular shape data of drug molecules.

C4X Discovery Holdings (FRA:C4J) Headlines

No Headlines